Nucleotide News and Research

RSS
Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Simple protocol for determining Gross Chromosomal Rearrangement mutation rates

Simple protocol for determining Gross Chromosomal Rearrangement mutation rates

GABRA2 gene influences brain’s reward responses to alcohol odors: Research

GABRA2 gene influences brain’s reward responses to alcohol odors: Research

International consortium publishes third-generation map of human genetic variation

International consortium publishes third-generation map of human genetic variation

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex completes INX-189 Phase1a trial for HCV

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Research confirms genetic link to advanced fatty liver disease

Research confirms genetic link to advanced fatty liver disease

New DNA sequencing method can lead to effective individualized medicine

New DNA sequencing method can lead to effective individualized medicine

Researchers discover genetic alterations responsible for Kabuki syndrome

Researchers discover genetic alterations responsible for Kabuki syndrome

Pharmasset receives fast track designation from FDA for PSI-7977

Pharmasset receives fast track designation from FDA for PSI-7977

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Pharmasset third-quarter net loss increases to $16.0 million

Pharmasset third-quarter net loss increases to $16.0 million

Celera decreases second-quarter net loss to $6.1 million

Celera decreases second-quarter net loss to $6.1 million

Researchers develop techniques to identify evolution of drug resistance strains of malaria

Researchers develop techniques to identify evolution of drug resistance strains of malaria

Scientists identify genetic basis for prostate cancer susceptibility in non-European population

Scientists identify genetic basis for prostate cancer susceptibility in non-European population

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Pharmasset announces data from PSI-352938 single ascending dose study

Pharmasset announces data from PSI-352938 single ascending dose study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.